Jubilant Pharmova share price today

Jubilant Pharmova Ltd's share price was ₹939.55 at the close on 4 November 2026. It has been falling for 12 weeks. That is 3.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹817 and ₹1,129, and at that close it sat 39% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Jubilant Pharmova Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 4 weeks in a row.

Over the last 11 years the share price moved +190% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) raised their stake for 14 quarters in a row, revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) and lowest operating margin in 12 quarters.

1. Indian funds and insurers (DIIs) raised their stake for 14 quarters in a row

   From 1.6% to 13% of the company by the September 2026 quarter.

2. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹2,229 crore, +17.3% on a year earlier.

3. Lowest operating margin in 12 quarters

   Operating margin was 11% in the June 2026 quarter, against 15% a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Jubilant Pharmova reported revenue of ₹2,229 crore, up 17.3% from ₹1,901 crore a year earlier, and a profit of ₹56.0 crore, down 45.1% from ₹102 crore.

Jubilant Pharmova results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 22 May 2026, about January to March 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Jubilant Pharmova closed at ₹939.55 on 4 November 2026, down 16.3% from ₹1,122.75 a year earlier (7 November 2025) and up 54.2% over five years. Its highest weekly close since March 2016 was ₹1,264.00 on 1 November 2024.

Jubilant Pharmova share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Jubilant Pharmova closed at ₹939.55, up 1.6% on the week and down 6.1% on the month. 24 Jul 2026: ex-date for a dividend of ₹5 a share.

Earlier

• Results for April to June 2026: Revenue up 17.3% and profit down 45.1% on a year earlier.
• 22 May 2026: Jubilant Pharmova held its results call for January to March 2026. Management guided: FY27 consolidated growth momentum to strengthen.

Jubilant Pharmova paid ₹5 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.53% at the ₹939.55 close on 4 November 2026. The last was a dividend of ₹5 a share, ex-date 24 July 2026.

Jubilant Pharmova dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Jubilant Pharmova Ltd paid out 20% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. 2 of those years show a negative figure because profit itself was negative.

From the NSE corporate-actions record, read 5 November 2026.

On the call for January to March 2026, held on 22 May 2026, Jubilant Pharmova's management guided: FY27 consolidated growth momentum to strengthen.

“We expect to reach peak revenue in Line 3 in 1.5 to 2 years earlier than projected and achieve 80-90 million specifically for Line 3”Chris Pretty, CEO CDMO Sterile Injectables, on the call for January to March 2026

What management guided

• FY27 operating margin two-halves story: H1 pressured by SPECT shortage, H2 recovery to 17-18% range.
• Line 3 commercial production late FY27, tech transfer revenue 60-80 million FY27.
• Line 3 peak revenue 80-90 million reached 1.5-2 years earlier than originally projected.
• Radiopharma FY27: low double-digit revenue growth, operating margin 38-40%.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for January to March 2026, 22 May 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.

When Jubilant Pharmova reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Line 3 commercial production confirmation by late FY27 and tech transfer revenue realization of 60-80 million; falsifiable against future earnings reports.

Jubilant Pharmova is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Jubilant Pharmova Ltd earned ₹56.0 Cr of net profit in the Jun 2026 quarter, −45.1% on the same quarter a year earlier. Full-year FY26 profit was ₹398 Cr. Over 10 years profit has grown 0.3% a year on average. That is 2.5% of the quarter's revenue. The same quarter a year earlier earned ₹102 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹398 Cr (−52.4% on the year before).

Why profit moved: revenue changed +17.3% on a year earlier and the margin moved −4.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −23.3% and revenue +16.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Jubilant Pharmova Ltd reported ₹2,229 Cr of revenue in the Jun 2026 quarter, +17.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 3.7% a year on average. The last full year, FY26, came in at ₹8,280 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹8,607 Cr.

FY26 revenue was ₹8,280 Cr, +14.5% on the year before.

Recent pace: the last four quarters grew +16.2% on average, against 3.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +16.2%, against +12.1% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −23.0%, against −20.0% a year (stabilising).

Jubilant Pharmova Ltd's operating margin was 11.0% in the Jun 2026 quarter, 4.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 11.0% and 26.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −4.1 percentage points on the year while gross margin changed −1.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 250% of Jubilant Pharmova Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,227 Cr of operating cash against ₹398 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹2,640 Cr of spending on assets, free cash was −₹1,413 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 250% of profit came in as cash: the cash cycle got 147 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 4.6× depreciation over three years. The next section checks what that spending is building.

Jubilant Pharmova Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 47 days in FY26, down from 194 days in FY21. It spent ₹5,452 Cr on assets over the last 3 years. Customers take 47 days to pay, and stock sits for 170 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹8,280 Cr, each day of that cycle ties up about ₹22.7 Cr, so roughly ₹1,066 Cr is tied up in the business at any time.

FY26: customers took 47 days to pay and stock sat for 170 days, about 5.6 months of sales sitting as stock, for a full cycle of 47 days, shorter than FY21's 194.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 170 days. Customers pay about 47 days after that. Suppliers are paid at 170 days. Together that makes the 47-day cycle.

Spending on assets: ₹5,452 Cr over the last 3 years, against ₹1,191 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹4,040 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Jubilant Pharmova Ltd's P/E is 38.5×, near the high end of its own history: higher than 82% of past readings. Its usual P/E (the middle reading) is 17.1×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹22.11.